Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib + Azacitidine in MDS/AML
NCT01926587Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Aug 2013
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rigosertib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Traws Pharma, Inc.. Started Aug 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01926587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926587.